Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
A £50 million research initiative, aimed at giving people '50 active years after 50' is being launched by the University of Leeds.
Modern tissue engineering developed at the University of Michigan could improve the function of prosthetic hands and possibly restore the sense of touch for injured patients.
SANUWAVE, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific findings titled “Extracorporeal Shock Wave Stimulation of Osteoprogenitor Cells” were presented at the 2009 International Bone-Tissue-Engineering Congress (“Bone-Tec”) in Hannover, Germany, which was held October 9-11, 2009.
University of Washington (UW) researchers have succeeded in engineering human tissue patches free of some problems that have stymied stem-cell repair for damaged hearts.
Joint Stock Company Human Stem Cell Institute” (“HSCI” or “the Company”), Russia’s leader in stem cell technology, today announced the preliminary price range for its initial public offering (“IPO”).
Stem cell researcher Treena Livingston Arinzeh will discuss current stem cell applications at NJIT, including the regeneration of bone and cartilage for bone fracture and osteoarthritis treatments, spinal cord repair, and liver regeneration at NJIT's first Research Caf.
New stem cell studies at the University of Maryland Dental School demonstrate that surgeons could one day routinely use strong, moldable, and injectable pastes to regenerate needed bone tissue to repair broken bones, fractures, genetic defects, even combat bone wounds.
Research led by a scientist at the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has shown injecting biomaterial gel into a spinal cord injury site provides significantly improved healing.
GENova Biotherapeutics Inc. ("GENova") is pleased to announce that it is in advanced negotiations to acquire a number of patents from TheraGlass Ltd., a company that produces a ground-breaking regenerative bioactive material with exciting potential applications.
A new grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health (NIH), will provide funding for University of Miami (UM) College of Engineering researchers to develop a novel bioreactor system that will control mechano-electrochemical environment for tissue growth and also provide on-line monitoring for the properties of engineered tissues.
Cardium Therapeutics (NYSE Amex: CXM) today reported on preclinical findings published in the scientific journal, Gene Therapy, demonstrating that Cardium's Gene Activated Matrix(TM) or GAM(TM) technology accelerates periodontal tissue regeneration of oral implant-supporting wounds.
The recipients of The 2009 Lasker Awards, announced today, represent the dramatic advances achieved in biotechnology research that have led to a revolutionary cancer treatment and the tremendous promise of stem cell therapy for regenerative medicine. Such advances portend a potential $700 million global market for new therapies within less than five years, according to Genetic Engineering & Biotechnology News (GEN, www.genengnews.com).
Virginia Tech College of Engineering researchers will use more than $1 million in grant funding to study engineered tissues that mimic the liver, one of the human body's most complex organs.
BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer, manufacturer, and marketer of biopreservation tools for cells, tissues, and organs, today announced that Sigma-Aldrich(R) will distribute the Company's proprietary HypoThermosol and CryoStor biopreservation media products under the terms of a non-exclusive distribution agreement.
LifeNet Health, a leading allograft bio-implant company, announces the first implant of a CardioGraft(TM) allograft cardiac patch product with MatrACELL(TM)( )decellularization technology. The surgery was performed at Children's Mercy Hospital in Kansas City, Mo by Gary K. Lofland, MD, FACS, Section Chief, Cardiovascular Surgery at Children's Mercy Hospital in Kansas City, Mo, The Joseph Boon Gregg/Missouri Endowed Chair in Pediatric Cardiac Surgery, Professor of Surgery, UMKC.
Insects are about to be analyzed in a new way by a host of Virginia Tech engineering faculty. They will be using some fancy state-of-the-art equipment, such as a kilometer-long synchrotron x-ray light source, which might be enough to scare any bug. And first up will be beetles, grasshoppers and silk moths because they have some endearing characteristics.
BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer, manufacturer, and marketer of biopreservation tools for cells, tissues, and organs, today announced the launch of its BloodStor biopreservation media product platform.
A novel electronic sensor array for more rapid, accurate and cost-efficient testing of DNA for disease diagnosis and biological research has been developed by scientists at Singapore's Institute of Bioengineering and Nanotechnology (IBN).
Utilizing fractal patterns similar to those created by lightning strikes, Victor Ugaz, associate professor in the Artie McFerrin Department of Chemical Engineering at Texas A&M University, has created a network of microchannels that could advance the field of tissue engineering by serving as a three-dimensional vasculature for the support of larger tissue constructs, such as human organs.
Although open-heart surgery is a frequent treatment for heart disease, it remains extremely dangerous. Now groundbreaking research from Dr. Britta Hardy of Tel Aviv University's Sackler School of Medicine has shown the potential for an injected protein to regrow blood vessels in the human heart ― eliminating the need for risky surgery altogether.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.